In view of our results and those obtained by others,43,50,52,85, 86, 87, 88,90 therapies based on sEH inhibition in metabolic syndrome should consider a potentially defective CYP-sEH pathway in metabolic tissues such as WAT and the liver of patients with obesity. Here, EPHX2 is linked to obesity disorder.